ArticleInternational urology and nephrology2020
Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia.
Article in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Current global estimates, risk factors, and knowledge gaps for Hepatitis E virus (HEV): A scoping review.PLoS neglected tropical diseases · 2026Article
- Prevalence of Viral Hepatitis Antibodies Among Alcoholics in Croatia: A Single Center's Results.Antibodies (Basel, Switzerland) · 2026Article
- Investigation of hepatitis E virus seroprevalence and risk factors in hemodialysis patients.Frontiers in public health · 2025Article
- Hepatitis E Virus (HEV) Infection among Hemodialysis Patients from Southern Bulgaria.Pathogens (Basel, Switzerland) · 2023Article
- Shifting perspectives in liver diseases after kidney transplantation.World journal of hepatology · 2023Review
- Hepatitis E Virus (HEV) Infection in Hemodialysis Patients: A Multicenter Epidemiological Cohort Study in North-Eastern Greece.Pathogens (Basel, Switzerland) · 2023Article
- Seroprevalence Trends and Molecular Epidemiology of Viral Hepatitis in Croatia.Life (Basel, Switzerland) · 2023Review
- Insights into hepatitis E virus epidemiology in Croatia.World journal of gastroenterology · 2022Article
- Status of anti-HEV IgG and IgM antibodies among the hemodialysis patients in southwest region of Iran.Iranian journal of microbiology · 2022Article
- Transfusion-transmitted hepatitis E: What we know so far?World journal of gastroenterology · 2022Review
- First Report of the HEV Seroprevalence and the Risk Factor Assessment in the West Bank, Palestine, during the Period of 2015-2017.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Hepatitis E Virus in Croatia in the "One-Health" Context.Pathogens (Basel, Switzerland) · 2021Review
- Emerging and Neglected Viruses of Zoonotic Importance in Croatia.Pathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeData on the seroprevalence of hepatitis E virus (HEV) in heamodialysis (HD) patients are conflicting, ranging from 0 to 44%. The aim of this study was to determine the HEV seroprevalence and risk factors among HD patients in Croatia.
methodsA total of 394 HD patients from six medical facilities in five Croatian cities (three sites in the continental and three sites in the coastal region) were tested for HEV IgM/IgG antibodies using an enzyme-linked immunosorbent assay. Additionally, all samples were tested for HEV RNA by RT-PCR. Sociodemographic data and risk factors were collected using a questionnaire.
resultsHEV IgG antibodies were detected in 110 (27.9%) patients. The seroprevalence varied significantly between dialysis centres, ranging from 5.2 to 43.4% (p = 0.001). HEV IgM antibodies were found in 0.04% of IgG positive patients. All patients tested negative for HEV RNA. Factors associated with HEV IgG seropositivity were age > 60 years (OR 8.17; 95% CI 1.08-62.14), living in the continental parts of the country (OR 2.58; 95% CI 1.55-4.30), and transfusion of blood products (OR 1.66; 95% CI 1.01-2.73). After adjusting for age and gender, patients from continental regions had higher odds of HEV seropositivity compared to patients from coastal regions (OR 2.88; 95% CI 1.71-4.85) and those who had RBC transfusions (OR 1.70, 95% CI 1.02-2.69) compared to those who did not.
conclusionThe study showed a high HEV seropositivity among HD patients in Croatia, with significant variations between geographical regions. Continental area of residence and RBC transfusion were the most significant risk factors for HEV seropositivity. Due to the high seroprevalence, routine HEV screening among HD patients, especially in transplant candidates should be considered.
Indexed as
Identifiers
31894559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.